Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319319 · ClinicalTrials.gov registry record · Phase 2
Nicotinic Receptor Augmentation of SSRI Antidepressants
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00319319 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 60 participants.
The verdict
NCT00319319, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized, placebo-controlled trial.
Interventions
- DRUG Mecamylamine hydrochloride (Inversine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-01 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319319
The ClinicalTrials.gov registry entry for NCT00319319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mecamylamine hydrochloride (Inversine) is the first listed.
NCT00319319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00319319 about?
NCT00319319 is a clinical study titled "Nicotinic Receptor Augmentation of SSRI Antidepressants". The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who are on stable doses of an SSR...
What is the current status of trial NCT00319319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2003-01. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00319319?
The interventions under investigation include: Mecamylamine hydrochloride (Inversine) (DRUG).
Who is sponsoring clinical trial NCT00319319?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.